Synthesis of PVA/γ-Fe2O3 Used in Cancer Treatment by Hyperthermia

Authors: Sajjad Seifi Mofarah, S. K. Sadrnezhaad, Shokooh Moghadam, Javad Tavakoli

Abstract:

In recent years a new method of combination treatment for cancer has been developed and studied that has led to significant advancements in the field of cancer therapy. Hyperthermia is a traditional therapy that, along with a creation of a medically approved level of heat with the help of an alternating magnetic AC current, results in the destruction of cancer cells by heat. This paper gives details regarding the production of the spherical nanocomposite PVA/γ-Fe2O3 in order to be used for medical purposes such as tumor treatment by hyperthermia. To reach a suitable and evenly distributed temperature, the nanocomposite with core-shell morphology and spherical form within a 100 to 200 nanometer size was created using phase separation emulsion, in which the magnetic nano-particles γ- Fe2O3 with an average particle size of 20 nano-meters and with different percentages of 0.2, 0.4, 0.5 and 0.6 were covered by polyvinyl alcohol. The main concern in hyperthermia and heat treatment is achieving desirable specific absorption rate (SAR) and one of the most critical factors in SAR is particle size. In this project all attempts has been done to reach minimal size and consequently maximum SAR. The morphological analysis of the spherical structure of the nanocomposite PVA/γ-Fe2O3 was achieved by SEM analyses and the study of the chemical bonds created was made possible by FTIR analysis. To investigate the manner of magnetic nanocomposite particle size distribution a DLS experiment was conducted. Moreover, to determine the magnetic behavior of the γ- Fe2O3 particle and the nanocomposite PVA/γ-Fe2O3 in different concentrations a VSM test was conducted. To sum up, creating magnetic nanocomposites with a spherical morphology that would be employed for drug loading opens doors to new approaches in developing nanocomposites that provide efficient heat and a controlled release of drug simultaneously inside the magnetic field, which are among their positive characteristics that could significantly improve the recovery process in patients.

Keywords: Nanocomposite, hyperthermia, cancer therapy, drug release.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1108741

References:

[1] Z.L. Wang and Z.C. Kang, functional and smart materials -Structural evolution and structure analysis, Georgia Institute of Technology, 1st edition, 1998.
[2] Sun, C., Lee, J. S. H. & Zhang, M. Magnetic nanoparticles in MR imaging and drug delivery. Advanced Drug Delivery Reviews 60, (2008).
[3] Varadan, V. K., Chen, L. &Xie, J. Nanomedicine: design and applications of magnetic nanomaterials, nanosensors and nanosystems. (Wiley, 2008).
[4] Gander B, Gurny R, Doelker E, Peppas NA (1983) ProcIntSymp Control Rel Pharm 5.
[5] Shang-Hsiu Hu, Ting-Yu Liu, Preparation and characterization of magnetic ferroscaffolds for tissue engineering, Journal of Magnetism and Magnetic Materials 310, 2871–2873,2007.
[6] D. Gopi, M. Thameem Ansari, E. Shinyjoy, L. Kavitha, Synthesis and spectroscopic characterization of magnetic hydroxyapatite nanocomposite using ultrasonic irradiation, SpectrochimicaActa Part A: Molecular and Biomolecular Spectroscopy, Volume 87, 15 February 2012, Pages 245-250.
[7] J. Giri, P. Pradhan, T. Sriharsha, D. Bahadur, Preparation and investigation of potentiality of different soft ferrites for hyperthermia applications, J. Appl. Phys. 97 (2005) 10Q916.
[8] Van den Berg CAT, Bartels LW, De Leeuw AAC, Lagendijk JJW, Van de Kamer JB. Experimental validation of hyperthermia SAR treatment planning using MR B1 imaging. Phys Med Biol 2004; 49(22):5029–42.
[9] S. Nagarajan, Z. Yong, Use of core/shell structured nanoparticles for biomedical applications, Recent Patents Biomed. Eng. 1 (2008) 34–42.
[10] G.V. Loo, X. Saelens, M.V. Gurp, M. MacFarlane, S.J. Martin, P. Vandenabeele, The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet, Cell Death Differ. 9 (2002) 1031- 1042.